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Surgical treatment retains its place in this setting in 
the form of cytoreductive nephrectomy 6,7. Further, 
the discovery of the von Hippel–Lindau (VHL) gene 
and the understanding gained of the molecular biol-
ogy of the disease have set the stage for an exciting 
new era of targeted therapies 8. However, the role of 
cytoreductive nephrectomy with the new tyrosine 
kinase inhibitors (t k i s) remains to be defined.
The present review touches on the indications 
and controversies surrounding surgical treatments 
for r c c . The evolution of surgical techniques and the 
introduction of laparoscopy are also discussed.
2.  SURGICAL TREATMENT FOR LOCALIZED 
RCC
2.1  Radical Nephrectomy
In 1963, Robson and colleagues published the seminal 
work that laid the foundations of surgical treatment 
for r c c  as we know it today 9,10. Key surgical steps 
in achieving adequate and safe oncologic control 
were identified, including early vascular control 
and renal excision preserving Gerota’s fascia, thus 
ensuring that surgical margins are away from the 
tumour. Other concepts put forward by Robson in-
cluded adrenal gland excision within Gerota’s fascia 
and extended ipsilateral lymphadenectomy from the 
crus of the diaphragm to the bifurcation of the aorta. 
These latter practices are not universally applied in 
the contemporary surgical approach, mostly because 
of a stage shift in r c c  toward localized disease and 
because of the new imaging modalities. Nonetheless, 
the description of a radical nephrectomy remains one 
of the pillars of the treatment of localized r c c ; all 
technical refinements developed thereafter have been 
guided by its basic principles.
Contemporary treatment of r c c  is a factor of tu-
mour size and location, presence of venous thrombus, 
and patient characteristics. Many incisions have been 
described, including flank, subcostal, midline, and 
thoraco-abdominal. Long-term oncologic results for 
open radical nephrectomy have been consistently re-
produced and serve as a benchmark for other surgical 
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1.  INTRODUCTION
Until recently, renal cell carcinoma (r c c ) was con-
sidered mainly a surgical disease, because it is, by 
and large, one of the most chemo- and radioresistant 
tumours. Since the first nephrectomy was performed 
for neoplastic disease by Langenbuch in 1877 1, huge 
strides have been made in refining the surgical indica-
tions and technical aspects of surgery for r c c. During 
the quarter century since the mid-1980s, new imaging 
modalities such as ultrasonography, computed tomog-
raphy (c t), and magnetic resonance imaging (m r i ) 
have come into widespread use. These diagnostic 
tests now allow for better preoperative staging and 
surgical planning of interventions. On the other hand, 
during that same period, imaging has also shifted the 
stage at which r c c  is being diagnosed and treated, 
and now a question arises: Is surgical treatment still 
indicated for very small renal lesions 2–4, which in 
many cases are turning out to have an indolent natural 
history? At the other end of the spectrum, patients 
suffering from advanced-stage r c c  have benefited 
from the introduction of systemic immune therapy, 
with some having complete and durable responses 5. SURGERY IN RENAL CELL CARCINOMA
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modalities. Although results from the initial series by 
Robson et al. showed a 5-year survival of 66% in lo-
calized disease 10, outcomes improved significantly in 
later studies. For patients with stage i disease, 5-year 
survival in contemporary series is now established at 
74%–95% 11–15. Table i shows contemporary 5- and 
10-year survival data after radical nephrectomy.
2.1.1  Role of Adrenalectomy
The incidence of adrenal metastasis from r c c  in 
contemporary series has been reported at 2.7%–
5.7% 16–19. This low occurrence, coupled with modern 
imaging modalities, has led to many questions about 
the role of systematic adrenalectomy during radical 
nephrectomy as initially suggested by Robson. Mo-
tivations for adrenal sparing include the possibility 
of relapse in the contralateral adrenal, the potential 
for hormone imbalances, and the desire to achieve 
shorter operative times. Indications for adrenalectomy 
vary according to author and include large tumours, 
upper pole tumours, and adrenal anomalies noted on 
preoperative imaging or intraoperatively 20.
In a large contemporary European series of 1179 
nephrectomies, Antonelli et al. found no adrenal 
metastases associated with tumours under 4 cm. 
Tumour location within the kidney was not predic-
tive of adrenal involvement, and imaging by c t  had 
a low sensitivity at 47%. Thus, the authors suggested 
the ipsilateral adrenal be spared only for tumours 
smaller than 4 cm, independent of tumour location, 
provided that preoperative imaging of the adrenal 
gland is normal 18. Another study by Siemer et al., also 
with a large sample (n = 1010), arrived at the same 
conclusions, underlining the importance of the 4-cm 
cut-off and the irrelevance of tumour location 21. It 
therefore seems prudent to consider clinical stage as 
the sole indication for adrenalectomy when radical 
nephrectomy is considered.
2.1.2  Role of Lymphadenectomy
Until recently, the role of lymphadenectomy in r c c  
surgery was a subject of controversy. Although the 
incidence of lymph node metastases as initially 
published by Robson et al. was 30%, modern series 
report occult metastases in only 3.3% of cases 10,22. 
However, even if lymphadenectomy may provide 
for accurate staging with no increased morbidity, its 
benefit with respect to survival and disease progres-
sion has not been established. A retrospective study 
of  r c c  surgical patients in the U.S. Surveillance, 
Epidemiology, and End Results database between 
1983 and 1998 showed no survival advantage when 
extensive lymphadenectomy was performed in local-
ized disease 23. Furthermore, the published results 
of the randomized phase iii European Organization 
for Research and Treatment of Cancer (e o r t c) 30881 
trial assessing radical nephrectomy with and without 
lymphadenectomy confirm the lack of a survival 
difference associated with the added lymph node 
dissection 24. However, the value of lymphadenec-
tomy in clinically node-positive patients undergoing 
cytoreductive nephrectomy for advanced disease 
remains to be clarified 25.
2.1.3  Surgery with Venous Thrombus
One particular challenge in r c c  surgery is macroscop-
ic tumoural extension into the venous system, namely 
the vena cava, which occurs in 5%–10% of cases 26. 
When r c c  is still localized in such a setting, surgery 
remains the mainstay of treatment 27,28. The largest 
series published to date on venous tumoural exten-
sion relates a multicentric experience from Europe, 
regrouping 1192 patients operated on between 1982 
and 2003 29. The authors reported median survivals 
of 52 months for thrombi limited to the renal vein, 
25.8 months for thrombi in the subdiaphragmatic 
vena cava, and 18 months for thrombi above the vena 
cava. A difference in survival was detected between 
tumours in the renal vein and those in the vena cava. 
However, the level of the tumour thrombus in the vena 
cava did not significantly affect survival.
The foregoing findings are very similar to results 
from the largest single-centre experience published to 
date from the Mayo clinic, where the 5-year survival 
was 49.1% for tumours limited to the renal vein and 
26.3%–39.4% for tumours in the vena cava 30. This 
last study—and others—also found statistically 
different survivals for renal vein as compared with 
vena cava thrombi, but the level of the thrombus in 
the vena cava was not predictive of survival 31. It 
seems, in fact, that biologic aggressiveness in such 
settings is dictated mainly by tumour grade and not 
t a b l e  i  Studies of 5- and 10-year survival in radical nephrectomy for renal cell carcinoma according to stage (i to iv)
Reference Survival (%)
5-Year 10-Year
i ii iii iV i ii iii iV
Kinouchi et al., 1999 11 99 92 70 24 93 73 49 19
Guinan et al., 1995 12 65 51 — — — — — —
Javidan et al., 1999 13 95 88 59 20 96 92 43 14
Tsui et al., 2000 14 83 57 42 28 — — — —
Gettman et al., 2001 15 99 90 66 39 97 84 53 32LATTOUF et al.
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by thrombus extension 32. Technical challenges are 
greater for thrombi extending above the diaphragm, 
because these necessitate cardiopulmonary bypass 
and a team approach. However, surgical refinements, 
including hepatic transplantation techniques and 
preoperative renal artery embolization, may help to 
circumvent this problem 33,34.
2.1.4  Laparoscopic Radical Nephrectomy
Laparoscopic radical nephrectomy was first described 
for neoplastic disease by Clayman et al. 35 in 1991. The 
many interesting advantages, including a lesser post-
operative analgesia requirement, shorter hospital stay, 
quicker convalescence, and improved cosmesis, have 
fuelled enthusiasm for this new approach and made it 
the preferred modality for localized r c c . Oncologic 
outcomes have been published with medium- and 
long-term follow-up 36–41 (Table ii), and comparative 
studies show equivalence of laparoscopic radical 
nephrectomy and the open approach 43–45.
Laparoscopy has been applied successfully to 
renal tumours as large as 16 cm 46—albeit follow-up 
for this patient population is still limited, and few 
publications are available. Furthermore, laparoscopic 
radical nephrectomy is feasible in the overweight 
patient, and although technically more challenging, 
this approach may result in superior perioperative 
outcomes as compared with the open technique 47. Fi-
nally, centres of expertise have reported laparoscopic 
radical nephrectomies with renal vein and vena cava 
tumour thrombi, confirming the safety and feasibility 
of the technique 48–50. In the view of many experts in 
the field, laparoscopic radical nephrectomy should 
be the standard of care for localized r c c  whenever 
technically feasible and when a partial nephrectomy 
is not indicated.
Access to the kidney may be obtained in a trans- 
or retroperitoneal fashion, with each route having 
its advantages and drawbacks. The retroperitoneal 
approach provides faster access to the renal hilum 
and may be the best choice for patients with pos-
terior tumours or with multiple prior abdominal 
surgeries. The transperitoneal approach remains 
the most popular, however, because it affords a 
larger working space and more familiar anatomic 
landmarks. Notwithstanding theses differences, 
both approaches seem to be equivalent in terms of 
perioperative outcome 51.
To ease the learning curve, hand-assisted laparo-
scopic radical nephrectomy (h a l r n ) was developed in 
parallel with the pure laparoscopic approach. It con-
sists of taking advantage of the incision from which 
the specimen is to be extracted to position a hand-
assist device that allows for the intra-abdominal intro-
duction of the operator’s hand. This technique offers 
the added advantage of tactile feedback and allows 
for manual compression when brisk bleeding is en-
countered. Although pure laparoscopic nephrectomy, 
as compared with h a l r n , may show a trend toward 
fewer complications in high-risk patients (American 
Society of Anesthesiologists score ≥3) 52, the h a l r n  
approach was shown to be equivalent to open radical 
nephrectomy on long-term follow-up 53.
2.2  Partial Nephrectomy
Initially, the indications for partial nephrectomy in 
malignant disease were limited to imperative condi-
tions, such as renal insufficiency, a solitary kidney, 
familial renal tumours, or underlying conditions 
that could jeopardize the contralateral renal unit. 
However, since the advent of c t  and magnetic reso-
nance imaging, a significant stage shift has occurred 
toward incidentally discovered smaller and localized 
renal lesions 4,54,55. In contrast with an overall rate of 
malignancy of 90%, these smaller tumours (<4 cm) 
tend to have a benign histology rate of up to 23% 56,57. 
Additionally, although nephrectomy in the younger 
population may not result in long-term functional 
impairment of global renal function 58, it has been 
shown that radical nephrectomy in the r c c  population 
may increase the lifetime risk for dialysis because of 
previous underlying medical conditions 59–61. These 
considerations, compounded by a risk of contralateral 
metachronous tumour recurrence of up to 4.25% 62,63, 
argue in favour of a nephron-sparing surgery (n s s ) 
approach, even in patients with normal contralateral 
renal units.
The goal of n s s  is to resect the tumour with nega-
tive margins, while preserving the largest possible 
amount of normal parenchyma. This procedure may 
involve a more complex set of technical steps than 
does radical nephrectomy, including preservation of 
the renal pedicle during hilar dissection, the need 
for kidney cooling during prolonged renal ischemia, 
and finally the need for a complex collecting system 
and vascular repair after tumoural resection. In some 
cases, the use of intraoperative ultrasound may also 
be required to delineate tumour location or the rela-
tionship of the tumour to major intrarenal vessels. 
Intraoperative frozen sections to rule out positive 
margins were advocated initially, but have not been 
universally adopted 64.
t a b l e  ii  Laparoscopic radical nephrectomy for T1–2 disease: 
overall survival with medium- and long-term follow-up
Reference Survival 
[cancer-specific/overall (%)]
5-Year 10-Year
Chan et al., 2001 37 85 / — —
Hemal et al., 2007 38 88 / 85.6 —
Ono et al., 1999 39 95 / — —
Permpongkosol et al., 2005 40 97 / 85 97 / 76
Saika et al., 2003 41 94 —
Portis et al., 2002 42 98 / 81 —SURGERY IN RENAL CELL CARCINOMA
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2.2.1  Open NSS
Studies on open n s s  with a normal contralateral kidney 
have shown that, for tumours under 4 cm in size, on-
cologic control in terms of 5- and 10-year survival is 
equivalent to that seen with radical nephrectomy 65–68. 
Partial nephrectomy has been attempted for larger tu-
mours, but follow-up of these patients in the literature 
is scarce 69–72. Overall, n s s  is not associated with more 
complications than is radical nephrectomy 73–75. It is 
thus widely accepted that partial nephrectomy consti-
tutes the “gold standard” for the treatment of localized 
r c c smaller than 4 cm.
The e o r t c  30904 randomized controlled study, 
whose objective was to compare n s s  with radical 
nephrectomy, has been completed. The results with 
regard to oncologic outcomes are awaited with great 
anticipation 76.
2.2.2  Laparoscopic NSS
Because of the complex technical steps involved in 
partial nephrectomy, the laparoscopic approach to 
this procedure was slow to emerge as a viable alter-
native. One of the main initial hurdles to overcome 
was hemostasis after parenchymal incision, and 
initial laparoscopic n s s  procedures were performed 
mainly for small exophytic renal lesions with very 
little parenchymal involvement. With evolving expe-
rience, intracorporeal knot-tying and hilar clamping 
emulating the open approach came into use, and 
the treatment of intraparenchymal lesions became 
feasible 77. Because of prolonged warm ischemia 
times at first, novel and innovative methods of cold 
ischemia have been described with varying degrees 
of success and varying advantages and caveats. 
These methods have included ice-slush cooling, 
intra-arterial cold saline perfusion, and collecting 
system cold perfusion using a ureteral catheter 78–81. 
However, renal cooling is less frequently used now, 
because clamping times have been significantly 
reduced with evolving experience.
Medium-term follow-up of oncologic outcomes 
with laparoscopic n s s  for small renal tumours is 
becoming available 82,83. The data reveal excellent 
results that are comparable to those achieved with the 
open approach. Increasingly larger and more com-
plex tumours are being managed using laparoscopic 
n s s  84,85. However, because of the complexity of the 
procedure and the paucity of long-term follow-up 
data, laparoscopic n s s  remains an approach under 
investigation that should be performed only in centres 
with the requisite experience.
2.2.3  Robotic NSS
Tele-robotic surgical systems have recently been 
introduced with the main goal of reducing the com-
plexity of intracorporeal suturing, often at difficult 
angles, as compared with conventional laparoscopy. 
Gettman et al. first described robot-assisted laparo-
scopic partial nephrectomy (r a l p n) in 2004 86. In 
the initial report of 13 cases by these authors, mean 
lesion size was 3.5 cm (range: 2.0–6.0 cm), mean 
operative time was 215 minutes (range: 130–262 
minutes), and mean blood loss was 170 mL (range: 
50–300 mL). Positive margins were reported in 
1 case (7.7%). The conclusion was that r a l p n is 
technically feasible and safe. One concern was the 
potential for delayed intervention in situations of 
urgent conversion such as massive hemorrhage. Nev-
ertheless, other groups have reported the feasibility 
and safety of r a l p n  87–93. Interestingly, Aron et al. 
published a matched-pair series that compared the 
experience between robotic and laparoscopic partial 
nephrectomy at the Cleveland Clinic 91. Overall, no 
differences were observed in perioperative variables 
(warm ischemia time, estimated blood loss, surgery 
time, length of stay). Fewer ports were used during 
laparoscopy. Renal functional outcomes, transfu-
sion rate, and complication rates were comparable. 
Two  r a l p n cases required conversion to standard 
laparoscopy. The authors concluded that r a l p n is a 
developing procedure and that further experience is 
necessary to determine the relative merits of r a l p n. 
At the date of writing, oncologic outcomes are yet 
to be determined, but r a l p n is not likely to improve 
surgical and oncologic outcomes over laparoscopy. 
It might, however, permit more urologists to perform 
this complex procedure, allowing it to evolve into 
mainstream practice.
3.  SURGICAL TREATMENT FOR METASTATIC 
RCC
3.1  Cytoreductive Nephrectomy
The rationale of cytoreductive nephrectomy in meta-
static r c c  is twofold: first, to remove a large tumour 
burden that could theoretically be immunosuppres-
sive, and second, to prevent potential local compli-
cations in the course of systemic therapy. Systemic 
therapy for r c c  has evolved over the past 20 years 
from immune-based agents such as interferon alfa 
and interleukin-2, to the most recent small-molecule 
inhibitors, including sorafenib, sunitinib, and temsi-
rolimus. In the setting of systemic immunotherapy, 
cytoreductive nephrectomy may be performed 
before treatment and has been shown to prolong 
survival in Southwest Oncology Group (s w o g ) and 
e o r t c  trials using interferon alfa 6,7,94. However, 
nephrectomy before immunotherapy has the caveat, 
in up to 60% of patients, of possible complications 
that may preclude these patients from ever receiv-
ing immunotherapy 95–97. Some investigators have 
therefore sought to assess systemic therapy as first-
line therapy so as to delineate responders, consider-
ing them to be the only candidates likely to benefit 
from subsequent surgery. Using this paradigm, the 
31%–50% of patients who are non-responders are 
spared the morbidity of nephrectomy 98,99.LATTOUF et al.
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The laparoscopic approach to cytoreductive ne-
phrectomy offers the advantage of reduced recovery 
time and perhaps the opportunity to initiate systemic 
therapy earlier than might occur with the open ap-
proach. Laparoscopic nephrectomy has been assessed, 
and Walthers et al. from the National Cancer Institute 
published a series in which the technique was shown 
to be safe and feasible 100.
In the era of t k i s, the role of cytoreductive ne-
phrectomy is not clearly defined. A discussion of 
the various trials pertaining to t k i  therapy for r c c  is 
beyond the scope of this review, and yet it should be 
emphasized that most patients assigned to treatment 
with a t k i  in randomized trials had already undergone 
nephrectomy. Thus, to remain comparable with the 
experimental setup, it seems reasonable to proceed to 
surgical cytoreduction in properly selected patients 
in the clinical setting.
3.2  Metastasectomy
Few studies are available on the effects of metasta-
sectomy, whether used alone or in combination with 
systemic therapy 101–103. It is commonly accepted that 
a better prognosis follows from resection of lung me-
tastases than from extrapulmonary lesions. Patients 
with synchronous metastases fare worse than do 
those with metachronous metastases. Furthermore, 
the longer the time from primary tumour resection 
to metastasectomy, the better the chances of achiev-
ing cure. The number of resectable metastases and 
the number of re-resections do not seem to affect 
the overall prognosis. Finally, a resection with the 
goal of achieving curative oncologic control results 
in far better survival than does palliative resection 
only. A retrospective study from the MD Ander-
son Cancer Center showed that, when it comes to 
exclusively local recurrence, surgery plus systemic 
therapy portends a 5-year survival of 50%, which 
is significantly superior to the survival seen with 
surgical resection alone 104.
4.  CONCLUSIONS
The surgical treatment of r c c  has evolved tremen-
dously since the end of the 1980s. It remains the most 
efficient modality to cure localized disease, and it is 
the “gold standard” by which newer, minimally inva-
sive therapies should be assessed. With the advent of 
new systemic therapies for r c c , many questions have 
been raised that remain to be answered concerning 
the role and timing of surgical cytoreduction. As 
with all other fields in oncology, the future of r c c  
surgery lies in identifying the patients that will even-
tually benefit the most from surgical treatment and 
in sparing those that will not. The ultimate answers 
will probably come from the discovery of novel bio-
markers, resulting in genetically tailored treatment 
for each individual patient.
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